The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease

被引：64
作者：
Kelsey, J. E. [1 ,2 ]
Harris, O. [2 ]
Cassin, J. [2 ]
机构：
[1] Bates Coll, Dept Psychol, Lewiston, ME 04240 USA
[2] Bates Coll, Program Neurosci, Lewiston, ME 04240 USA
来源：
BEHAVIOURAL BRAIN RESEARCH | 2009年 / 203卷 / 02期
关键词：
Parkinson's; 6-OHDA; Rimonabant; CB1; receptors; L-DOPA; Forepaw stepping; RECEPTOR MESSENGER-RNA; MEDIAL FOREBRAIN-BUNDLE; DOPAMINERGIC-NEURONS; RAT MODEL; 6-HYDROXYDOPAMINE; LOCALIZATION; INJECTIONS; LESIONS;
D O I：
10.1016/j.bbr.2009.04.035
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
Acute injections of 8 mg/kg of 3,4-dihydroxy-L-phenylaianine (L-DOPA) or 0.05 mg/kg rimonabant equally improved contralateral forepaw stepping in rats with unilateral 6-hydroxydopamine (6-OHDA) lesions, and their combination improved stepping more than either drug alone. However, 0.05 mg/kg rimonabant did not alter the changes in stepping produced by acute injections of a dyskinesic dose of 35 mg/kg L-DOPA. Thus, not only is a cannabinoid antagonist monotherapeutic in this animal model of Parkinson's disease, but it also enhances the therapeutic effect of a moderate, but not a high, dose Of L-DOPA. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码：304 / 307
页数：4
相关论文
共 17 条
  • [1] Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: Studies on medial forebrain bundle and striatal lesions
    Chang, JW
    Wachtel, SR
    Young, D
    Kang, UJ
    [J]. NEUROSCIENCE, 1999, 88 (02) : 617 - 628
  • [2] CHEN M, 2007, 2007 NEUR M PLANN SA
  • [3] Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism
    Fernandez-Espejo, E
    Caraballo, I
    de Fonseca, FR
    El Banoua, F
    Ferrer, B
    Flores, JA
    Galan-Rodriguez, B
    [J]. NEUROBIOLOGY OF DISEASE, 2005, 18 (03) : 591 - 601
  • [4] Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
    González, S
    Scorticati, C
    García-Arencibia, M
    de Miguel, R
    Ramos, JA
    Fernández-Ruiz, J
    [J]. BRAIN RESEARCH, 2006, 1073 : 209 - 219
  • [5] Hohmann AG, 2000, SYNAPSE, V37, P71, DOI 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO
  • [6] 2-K
  • [7] NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats
    Kelsey, JE
    Mague, SD
    Pijanowski, RS
    Harris, RC
    Kleckner, NW
    Matthews, RT
    [J]. PSYCHOPHARMACOLOGY, 2004, 175 (02) : 179 - 188
  • [8] The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat
    Kelsey, John E.
    Langelier, Nicole A.
    Oriel, Brad S.
    Reedy, Catherine
    [J]. PSYCHOPHARMACOLOGY, 2009, 201 (04) : 529 - 539
  • [9] Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
    Kirik, D
    Rosenblad, C
    Björklund, A
    [J]. EXPERIMENTAL NEUROLOGY, 1998, 152 (02) : 259 - 277
  • [10] Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets
    Lastres-Becker, I
    Cebeira, M
    de Ceballos, ML
    Zeng, BY
    Jenner, P
    Ramos, JA
    Fernández-Ruiz, JJ
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2001, 14 (11) : 1827 - 1832
12